Cancers in Patients with von Willebrand Disease: A Survey from the Italian Association of Haemophilia Centres

Abstract

Besides its essential role in hemostasis, there is growing evidence that von Willebrand factor (VWF) has an additional antitumor effect. To elucidate the clinical significance of this biological activity we conducted a retrospective study on cancers among Italian patients with von Willebrand disease (VWD) on behalf of the Italian Association of Haemophilia Centres (AICE). A questionnaire to collect demographic, clinical, and treatment data of VWD patients with cancer was sent to all the 54 Italian Haemophilia Treatment Centres (HTCs) members of AICE. Overall, 18 HTCs (33%) provided information on 92 VWD patients (61 alive and 31 deceased) with 106 cancers collected during the period 1981 to 2014. Of them, 19 (18%) were hematological cancers and 87 (82%) were solid cancers. A total of 61% of patients had type 1, 36% type 2 (12% type 2A, 14% type 2B, 9% type 2M, and 1% type 2N), and 3% type 3 VWD: this distribution was significantly different from that observed in the whole VWD population (79% type 1, 16% type 2 [8% type 2A, 4% type 2B, 2% type 2M, 2% type 2N], and 5% type 3; type 2 vs. non-type 2: p < 0.001). Overall, VWD patients with cancer underwent 52 invasive and 72 surgical procedures, were treated with VWF/factor VIII (FVIII) concentrates in 77 cases, with desmopressin (DDAVP) alone in 24 cases and with DDAVP and VWF/FVIII concentrates in 7 cases. Hemorrhagic complications were observed only rarely (2% of invasive procedures and radiotherapy and 6% of surgical interventions). The data collected by this survey document that a substantial number of cancers are recorded among VWD patients and that these patients are safely managed by HTC physicians through a multidisciplinary approach.

Keywords

von Willebrand disease - cancer - bleeding - mortality

^* The complete list of coauthors for the study (Italian Association of Haemophilia Centres, with the site of the Haemophilia Centre given in parentheses, is as follows.

Cosimo Ettorre and Renato Marino (Bari); Piergiorgio Iannaccaro (Catanzaro); Flora Peyvandi (Milano); Giovanni Di Minno (Napoli); Gianna Franca Rivolta and Gabriele Quintavalle (Parma); Alfredo Dragani (Pescara); Silvia Macchi (Ravenna); Gianluca Sottilotta (Reggio Calabria); Attilia Maria Pizzini (Reggio Emilia); Maria Gabriella Mazzucconi (Roma); Piercarla Schinco (Torino); Anna Chiara Giuffrida (Verona).

• References

• 1 Ruggeri ZM. Structure of von Willebrand factor and its function in platelet adhesion and thrombus formation. Best Pract Res Clin Haematol 2001; 14 (2) 257-279
• 2 Franchini M, Lippi G. The role of von Willebrand factor in hemorrhagic and thrombotic disorders. Crit Rev Clin Lab Sci 2007; 44 (2) 115-149
• 3 Castaman G, Federici AB, Rodeghiero F, Mannucci PM. Von Willebrand's disease in the year 2003: towards the complete identification of gene defects for correct diagnosis and treatment. Haematologica 2003; 88 (1) 94-108
• 4 Franchini M, Frattini F, Crestani S, Bonfanti C, Lippi G. von Willebrand factor and cancer: a renewed interest. Thromb Res 2013; 131 (4) 290-292
• 5 Starke RD, Ferraro F, Paschalaki KE , et al. Endothelial von Willebrand factor regulates angiogenesis. Blood 2011; 117 (3) 1071-1080
• 6 Terraube V, Pendu R, Baruch D , et al. Increased metastatic potential of tumor cells in von Willebrand factor-deficient mice. J Thromb Haemost 2006; 4 (3) 519-526
• 7 Terraube V, Marx I, Denis CV. Role of von Willebrand factor in tumor metastasis. Thromb Res 2007; 120 (Suppl. 02) S64-S70
• 8 Hatzipantelis ES, Athanassiou-Metaxa M, Gombakis N , et al. Thrombomodulin and von Willebrand factor: relation to endothelial dysfunction and disease outcome in children with acute lymphoblastic leukemia. Acta Haematol 2011; 125 (3) 130-135
• 9 Schellerer VS, Mueller-Bergh L, Merkel S , et al. The clinical value of von Willebrand factor in colorectal carcinomas. Am J Transl Res 2011; 3 (5) 445-453
• 10 Wang WS, Lin JK, Lin TC , et al. Plasma von Willebrand factor level as a prognostic indicator of patients with metastatic colorectal carcinoma. World J Gastroenterol 2005; 11 (14) 2166-2170
• 11 Zietek Z, Iwan-Zietek I, Paczulski R, Kotschy M, Wolski Z. von Willebrand factor antigen in blood plasma of patients with urinary bladder carcinoma. Thromb Res 1996; 83 (5) 399-402
• 12 Gadducci A, Baicchi U, Marrai R, Del Bravo B, Fosella PV, Facchini V. Pretreatment plasma levels of fibrinopeptide-A (FPA), D-dimer (DD), and von Willebrand factor (vWF) in patients with ovarian carcinoma. Gynecol Oncol 1994; 53 (3) 352-356
• 13 Kim SM, Myoung H, Choung PH, Kim MJ, Lee SK, Lee JH. Metastatic leiomyosarcoma in the oral cavity: case report with protein expression profiles. J Craniomaxillofac Surg 2009; 37 (8) 454-460
• 14 Jiang WG, Watkins G, Douglas-Jones A, Holmgren L, Mansel RE. Angiomotin and angiomotin like proteins, their expression and correlation with angiogenesis and clinical outcome in human breast cancer. BMC Cancer 2006; 6: 16
• 15 Josefsson A, Wikström P, Granfors T , et al. Tumor size, vascular density and proliferation as prognostic markers in GS 6 and GS 7 prostate tumors in patients with long follow-up and non-curative treatment. Eur Urol 2005; 48 (4) 577-583
• 16 Gallego L, Junquera L. Association von Willebrand's disease and nevoid basal cell carcinoma syndrome (Gorlin syndrome). Haemophilia 2008; 14 (4) 835-837
• 17 Bercaw JL, Sanchez J, Byrd RH, Bhattacharjee MB, Dietrich JE. Sex cord tumor with annular tubules in a young adolescent with Von Willebrand's disease. J Pediatr Adolesc Gynecol 2010; 23 (3) e111-e114
• 18 Boldorini R, Allegrini S, Tognon M , et al. Merkel cell carcinoma arising in inguinal lymph node in a patient with von Willebrand disease after multiple blood transfusions. J Clin Virol 2014; 60 (1) 73-75
• 19 Trousseau A. Phlegmasia alba dolens. In: Trousseau A, , ed. Clinique medicinale de l'Hotel-Dieu de Paris. Paris, France: JB Bailliere et fils; 1865: 645-712
• 20 Hu L, Lee M, Campbell W, Perez-Soler R, Karpatkin S. Role of endogenous thrombin in tumor implantation, seeding, and spontaneous metastasis. Blood 2004; 104 (9) 2746-2751
• 21 Franchini M, Montagnana M, Targher G, Manzato F, Lippi G. Pathogenesis, clinical and laboratory aspects of thrombosis in cancer. J Thromb Thrombolysis 2007; 24 (1) 29-38
• 22 Langer F, Amirkhosravi A, Ingersoll SB , et al. Experimental metastasis and primary tumor growth in mice with hemophilia A. J Thromb Haemost 2006; 4 (5) 1056-1062
• 23 Brüggemann LW, Versteeg HH, Niers TM, Reitsma PH, Spek CA. Experimental melanoma metastasis in lungs of mice with congenital coagulation disorders. J Cell Mol Med 2008; 12 (6B): 2622-2627
• 24 Franchini M, Mannucci PM. Thrombin and cancer: from molecular basis to therapeutic implications. Semin Thromb Hemost 2012; 38 (1) 95-101
• 25 Franchini M, Mannucci PM. Low-molecular-weight heparins and cancer: Focus on antitumoral effect. Ann Med 2015; 47 (2) 116-121
• 26 Cunningham MS, Preston RJS, O'Donnell JS. Does antithrombotic therapy improve survival in cancer patients?. Blood Rev 2009; 23 (3) 129-135
• 27 Sanford D, Naidu A, Alizadeh N, Lazo-Langner A. The effect of low molecular weight heparin on survival in cancer patients: an updated systematic review and meta-analysis of randomized trials. J Thromb Haemost 2014; 12 (7) 1076-1085
• 28 Franchini M, Lippi G, Montagnana M , et al. Hemophilia and cancer: a new challenge for hemophilia centers. Cancer Treat Rev 2009; 35 (4) 374-377
• 29 Franchini M. Haemophilia and cancer: a personal perspective. Blood Transfus 2013; 11 (1) 26-31
• 30 Dunn AL. Malignancy in patients with haemophilia: a review of the literature. Haemophilia 2010; 16 (3) 427-436
• 31 Miesbach W, Seifried E. Does haemophilia influence cancer-related mortality in HIV-negative patients?. Haemophilia 2011; 17 (1) 55-60
• 32 Tagliaferri A, Di Perna C, Santoro C , et al; Italian Association of Hemophilia Centers. Cancers in patients with hemophilia: a retrospective study from the Italian Association of Hemophilia Centers. J Thromb Haemost 2012; 10 (1) 90-95
• 33 Mannucci PM. Desmopressin (DDAVP) in the treatment of bleeding disorders: the first 20 years. Blood 1997; 90 (7) 2515-2521
• 34 Marcucci F, Mele A. Hepatitis viruses and non-Hodgkin lymphoma: epidemiology, mechanisms of tumorigenesis, and therapeutic opportunities. Blood 2011; 117 (6) 1792-1798
• 35 Franchini M, Mannucci PM. Gastrointestinal angiodysplasia and bleeding in von Willebrand disease. Thromb Haemost 2014; 112 (3) 427-431
• 36 Federici AB, Bucciarelli P, Castaman G , et al. The bleeding score predicts clinical outcomes and replacement therapy in adults with von Willebrand disease. Blood 2014; 123 (26) 4037-4044